Compare AJANTA PHARMA with Piramal Enterprises - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA PIRAMAL ENTERPRISES AJANTA PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 27.1 -37.8 - View Chart
P/BV x 6.7 1.3 525.6% View Chart
Dividend Yield % 0.5 1.8 28.9%  

Financials

 AJANTA PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
PIRAMAL ENTERPRISES
Mar-19
AJANTA PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,4223,303 43.1%   
Low Rs8981,797 50.0%   
Sales per share (Unadj.) Rs233.5716.5 32.6%  
Earnings per share (Unadj.) Rs44.079.7 55.2%  
Cash flow per share (Unadj.) Rs52.2107.9 48.3%  
Dividends per share (Unadj.) Rs9.0028.00 32.1%  
Dividend yield (eoy) %0.81.1 70.7%  
Book value per share (Unadj.) Rs255.11,477.5 17.3%  
Shares outstanding (eoy) m88.02184.45 47.7%   
Bonus/Rights/Conversions BBIS-  
Price / Sales ratio x5.03.6 139.6%   
Avg P/E ratio x26.432.0 82.5%  
P/CF ratio (eoy) x22.223.6 94.1%  
Price / Book Value ratio x4.51.7 263.5%  
Dividend payout %20.535.1 58.3%   
Avg Mkt Cap Rs m102,081470,292 21.7%   
No. of employees `0006.87.8 87.0%   
Total wages/salary Rs m4,30722,504 19.1%   
Avg. sales/employee Rs Th3,022.616,899.4 17.9%   
Avg. wages/employee Rs Th633.42,877.7 22.0%   
Avg. net profit/employee Rs Th569.11,879.9 30.3%   
INCOME DATA
Net Sales Rs m20,554132,153 15.6%  
Other income Rs m2113,128 6.7%   
Total revenues Rs m20,765135,281 15.3%   
Gross profit Rs m5,66466,290 8.5%  
Depreciation Rs m7215,202 13.9%   
Interest Rs m1244,097 0.0%   
Profit before tax Rs m5,14320,119 25.6%   
Minority Interest Rs m03,194 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,2738,611 14.8%   
Profit after tax Rs m3,87014,701 26.3%  
Gross profit margin %27.650.2 54.9%  
Effective tax rate %24.842.8 57.8%   
Net profit margin %18.811.1 169.2%  
BALANCE SHEET DATA
Current assets Rs m11,812122,742 9.6%   
Current liabilities Rs m3,776310,810 1.2%   
Net working cap to sales %39.1-142.3 -27.5%  
Current ratio x3.10.4 792.1%  
Inventory Days Days7723 335.5%  
Debtors Days Days8239 210.1%  
Net fixed assets Rs m14,398116,904 12.3%   
Share capital Rs m175369 47.5%   
"Free" reserves Rs m22,277272,161 8.2%   
Net worth Rs m22,452272,530 8.2%   
Long term debt Rs m7270,196 0.0%   
Total assets Rs m26,962856,261 3.1%  
Interest coverage x444.31.5 30,512.7%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x0.80.2 493.9%   
Return on assets %14.46.9 209.6%  
Return on equity %17.25.4 319.5%  
Return on capital %23.012.4 184.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,68215,200 70.3%   
Fx outflow Rs m2,1024,889 43.0%   
Net fx Rs m8,58010,312 83.2%   
CASH FLOW
From Operations Rs m3,748-115,975 -3.2%  
From Investments Rs m-2,228-8,265 27.0%  
From Financial Activity Rs m-1,475107,525 -1.4%  
Net Cashflow Rs m45-16,650 -0.3%  

Share Holding

Indian Promoters % 73.8 52.9 139.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 4.0 38.8%  
FIIs % 7.6 26.6 28.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 16.5 103.0%  
Shareholders   20,968 93,274 22.5%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   BIOCON   WOCKHARDT  VENUS REMEDIES  DR. DATSONS LABS  GLENMARK PHARMA  

Compare AJANTA PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

SGX Nifty Up 126 Points; Indicates Gap-Up Opening for Indian Stock Markets(SGX Nifty)

The SGX Nifty opened on a positive note today. At 8:10 am, it was trading up by 126 points, or 0.87% higher at 14,480 levels.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY21); Net Profit Up 22.1% (Quarterly Result Update)

Aug 25, 2020 | Updated on Aug 25, 2020

For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 45.3% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 45.3% YoY). Sales on the other hand came in at Rs 7 bn (up 32.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 60.8% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 60.8% YoY). Sales on the other hand came in at Rs 7 bn (up 34.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

Buzzing Sectors Before Budget 2021(Fast Profits Daily)

Jan 12, 2021

The budget is just a few weeks away. Which stocks can you expect to move? Find out in this video.

Here's Why Smallcaps Could Be Your Best Investment in 2021(Profit Hunter)

Jan 12, 2021

Select smallcaps hold a great potential to become the multibaggers of tomorrow. Here's how you could get in early into these stocks.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 25, 2021 09:12 AM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS